These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16557866)

  • 1. Further in vitro studies with 5-fluorocytosine.
    Shadomy S
    Infect Immun; 1970 Oct; 2(4):484-8. PubMed ID: 16557866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
    Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
    Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-fluorocytosine resistance in Cryptococcus neoformans.
    Block ER; Jennings AE; Bennett JE
    Antimicrob Agents Chemother; 1973 Jun; 3(6):649-56. PubMed ID: 4597734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antimycotic activity of 5-fluorocytosine.
    Holt RJ; Newman RL
    J Clin Pathol; 1973 Mar; 26(3):167-74. PubMed ID: 4700499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of 5-fluorocytosine against Candida and Torulopsis species.
    Shadomy S; Kirchoff CB; Ingroff AE
    Antimicrob Agents Chemother; 1973 Jan; 3(1):9-14. PubMed ID: 4799552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of 5-fluorocytosine on nucleic acid synthesis in Candida albicans, Cryptococcus neoformans, and Aspergillus fumigatus.
    Polak A; Wain WH
    Chemotherapy; 1977; 23(4):243-59. PubMed ID: 324722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variables influencing susceptibility testing of Cryptococcus neoformans to 5-fluorocytosine.
    Block ER; Jennings AE; Bennett JE
    Antimicrob Agents Chemother; 1973 Oct; 4(4):392-5. PubMed ID: 4598611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined in vitro activity of amphotericin B and 5-fluorocytosine against Cryptococcus neoformans and Candida albicans.
    Chen HH; Liushih RN; Hsieh WC
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1982 May; 15(2):106-12. PubMed ID: 7047097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The resistance behavior of yeast isolates from defined patient groups to 5-fluorocytosine].
    Weber S; Polak-Wyss A
    Mycoses; 1991; 34 Suppl 1():77-81. PubMed ID: 1818269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro studies with 5-fluorocytosine.
    Shadomy S
    Appl Microbiol; 1969 Jun; 17(6):871-7. PubMed ID: 5797940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiological investigation of non-albicans Candida species recovered from mycotic mastitis of cows in Yinchuan, Ningxia of China.
    Du J; Wang X; Luo H; Wang Y; Liu X; Zhou X
    BMC Vet Res; 2018 Aug; 14(1):251. PubMed ID: 30157847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative evaluation of PASCO and national committee for clinical laboratory standards M27-A broth microdilution methods for antifungal drug susceptibility testing of yeasts.
    Arthington-Skaggs BA; Motley M; Warnock DW; Morrison CJ
    J Clin Microbiol; 2000 Jun; 38(6):2254-60. PubMed ID: 10834985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility of yeast isolates from defined German patient groups to 5-fluorocytosine.
    Weber S; Polak A
    Mycoses; 1992; 35(7-8):163-71. PubMed ID: 1287480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro studies of 5-fluorocytosine resistance in Candida albicans and Torulopsis glabrata.
    Normark S; Schönebeck J
    Antimicrob Agents Chemother; 1972 Sep; 2(3):114-21. PubMed ID: 4597703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifungal drug resistance in pathogenic fungi.
    Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D
    Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice.
    Polak A; Scholer HJ; Wall M
    Chemotherapy; 1982; 28(6):461-79. PubMed ID: 6297858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The genetic basis of resistance to 5-fluorocytosine in Candida species and Cryptococcus neoformans.
    Whelan WL
    Crit Rev Microbiol; 1987; 15(1):45-56. PubMed ID: 3319420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients.
    Hoban DJ; Zhanel GG; Karlowsky JA
    Antimicrob Agents Chemother; 1999 Jun; 43(6):1463-4. PubMed ID: 10348771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antifungal activity of 5-fluorocytosine as measured by disk diffusion susceptibility testing.
    Utz CJ; Shadomy S
    J Infect Dis; 1977 Jun; 135(6):970-4. PubMed ID: 325150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.
    Schwarz P; Dromer F; Lortholary O; Dannaoui E
    Antimicrob Agents Chemother; 2006 Jan; 50(1):113-20. PubMed ID: 16377675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.